Abstract:Background: Prognosis for patients with original glioblastoma diagnosis remains poor. Antiangiogenic therapy with Bevacizumab in first line treatment did not lead to improvement in overall survival, while progression-free survival was prolonged by 3 to 4 months, in recent phase III studies. Bevacizumab therapy in glioblastomas is not successfully associated with any prognostic biological markers. Our study investigates the correlation between the use of bevacizumab and several clinical and molecular markers me… Show more
Background and Aims: Glioblastoma multiforme, a grade IV astrocytoma, is the most common primary brain tumor in adults. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal IgG1 antibody, is a Food and Drug Administration-approved agent for the treatment of advanced Glioblastoma multiforme. In this review, we aimed to discuss the therapeutic effects of bevacizumab for Glioblastoma multiforme treatment.
Methods: We searched Google scholar, PubMed, and Scopus using keywords “Glioblastoma multiforme,” “GBM,” and “Bevacizumab.” Two authors screened the records to identify relevant studies and classify them according to our outcomes of interest.
Results: Bevacizumab selectively binds circulating VEGF, interfering with the role of VEGF in endothelial cell differentiation, sprouting, and capillary formation. Consequently, it inhibits tumor neovascularization and induces the development of normal vascular structures
Conclusions: Our review summarized some factors that may maximize the effectiveness of the drug at the lowest possible cost. We mention limitations of bevacizumab use and put forward solutions. Despite progress, many questions remain unanswered; therefore, further well-designed studies are required to investigate the optimal management of Glioblastoma multiforme treatment with bevacizumab.
Background and Aims: Glioblastoma multiforme, a grade IV astrocytoma, is the most common primary brain tumor in adults. Bevacizumab, a humanized anti-vascular endothelial growth factor monoclonal IgG1 antibody, is a Food and Drug Administration-approved agent for the treatment of advanced Glioblastoma multiforme. In this review, we aimed to discuss the therapeutic effects of bevacizumab for Glioblastoma multiforme treatment.
Methods: We searched Google scholar, PubMed, and Scopus using keywords “Glioblastoma multiforme,” “GBM,” and “Bevacizumab.” Two authors screened the records to identify relevant studies and classify them according to our outcomes of interest.
Results: Bevacizumab selectively binds circulating VEGF, interfering with the role of VEGF in endothelial cell differentiation, sprouting, and capillary formation. Consequently, it inhibits tumor neovascularization and induces the development of normal vascular structures
Conclusions: Our review summarized some factors that may maximize the effectiveness of the drug at the lowest possible cost. We mention limitations of bevacizumab use and put forward solutions. Despite progress, many questions remain unanswered; therefore, further well-designed studies are required to investigate the optimal management of Glioblastoma multiforme treatment with bevacizumab.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.